P2Y12 inhibitors: Difference between revisions
(Created page with "'''P2Y<sub>12</sub> inhibitors''' are antiplatelet drugs. They are are often used in combination with acetylsalicylic acid, which is called ''dual antiplatelet therapy'' (<abbr>DAPT</abbr>). However, they may also be used alone. == Compounds == * Clopidogrel (Plavix®) * Prasugrel (Efient®) * Ticagrelor (Brilique®) == Mechanism of action == These drugs inhibit the P2Y12 receptor, an ADP receptor which is found on platelets. This receptor binds ADP which is r...") |
No edit summary |
||
| Line 1: | Line 1: | ||
'''P2Y<sub>12</sub> inhibitors''' are [[antiplatelet drugs]]. They are are often used in combination with [[acetylsalicylic acid]], which is called ''dual antiplatelet therapy'' (<abbr>DAPT</abbr>). However, they may also be used alone. | <section begin="clinical biochemistry" />'''P2Y<sub>12</sub> inhibitors''' are [[antiplatelet drugs]]. They are are often used in combination with [[acetylsalicylic acid]], which is called ''dual antiplatelet therapy'' (<abbr>DAPT</abbr>). However, they may also be used alone.<section end="clinical biochemistry" /> | ||
== Compounds == | == Compounds == | ||
* Clopidogrel (Plavix®) | * Clopidogrel (Plavix®) | ||
* Prasugrel (Efient®) | * Prasugrel (Efient®) | ||
| Line 12: | Line 11: | ||
== Pharmacokinetics == | == Pharmacokinetics == | ||
Clopidogrel and prasugrel are irreversible inhibitors, while ticagrelor is a reversible inhibitor. They have similar half-lives but the effect lasts longer for the irreversible inhibitors, as new platelets must be formed for the effect to pass. | Clopidogrel and prasugrel are irreversible inhibitors, while ticagrelor is a reversible inhibitor. They have similar half-lives but the effect lasts longer for the irreversible inhibitors, as new platelets must be formed for the effect to pass. | ||
<noinclude>[[Category:Pharmacology]] | |||
== Monitoring == | |||
<section begin="clinical biochemistry" />One can monitor P2Y<sub>12</sub> therapeutic effect with [[platelet aggregometry]] with ADP, but this is not routinely performed. There are no known uses for this, as a therapeutic reference range has not been established.<section end="clinical biochemistry" /><noinclude> | |||
[[Category:Pharmacology]] | |||
</noinclude> | </noinclude> | ||
Latest revision as of 13:03, 28 April 2024
P2Y12 inhibitors are antiplatelet drugs. They are are often used in combination with acetylsalicylic acid, which is called dual antiplatelet therapy (DAPT). However, they may also be used alone.
Compounds
- Clopidogrel (Plavix®)
- Prasugrel (Efient®)
- Ticagrelor (Brilique®)
Mechanism of action
These drugs inhibit the P2Y12 receptor, an ADP receptor which is found on platelets. This receptor binds ADP which is released from other activated platelets. By blocking the P2Y12 receptor these drugs prevent platelet aggregation.
Pharmacokinetics
Clopidogrel and prasugrel are irreversible inhibitors, while ticagrelor is a reversible inhibitor. They have similar half-lives but the effect lasts longer for the irreversible inhibitors, as new platelets must be formed for the effect to pass.
Monitoring
One can monitor P2Y12 therapeutic effect with platelet aggregometry with ADP, but this is not routinely performed. There are no known uses for this, as a therapeutic reference range has not been established.